Journal Watch · Journal of Controlled Release · 2026
Multiaspect layered double hydroxide nanohybrid counteracts pathophysiological cascade for ischemic stroke intervention.
This multi-targeted nanosheet offers spatiotemporally controlled therapy for IS, addressing its complex pathogenesis.
TL;DR
This multi-targeted nanosheet offers spatiotemporally controlled therapy for IS, addressing its complex pathogenesis.
Key findings
- In a mouse model of transient ischemia, S-E@LDH reduces neuronal damage, neuroinflammation and cerebral edema, improving motor function.
- This multi-targeted nanosheet offers spatiotemporally controlled therapy for IS, addressing its complex pathogenesis.
What they did
In the acute phase, cellular damage is reduced by effectively chelating Ca<sup>2+</sup>, scavenging reactive oxygen/nitrogen and disrupting the Ca<sup>2+</sup>-ROS amplification loop. Importantly, SAA stabilized in the LDH matrix undergoes spatiotemporally controlled release relying on the acidic pH of the post-ischemic environment, and targeted, precise administration reprograms microglia to an M2 phenotype, helping to restore brain homeostasis.
Full abstract (original)
Background: Ischemic stroke (IS) therapy remains challenging due to dynamic ischemia-reperfusion pathology. Here, we propose a hybrid nanosheet platform (S-E@LDH) consisting of a layered double hydroxide (LDH) matrix MgAlRu with broad-spectrum enzyme mimetic activity, with the addition of the calcium chelator ethylene glycol tetraacetic acid (EGTA) and the anti-inflammatory agent salvianic acid A (SAA), which rationally integrates the "calcium dysregulation-oxidative stress-inflammation" triple synergistic regulation mode.
What they did: In the acute phase, cellular damage is reduced by effectively chelating Ca<sup>2+</sup>, scavenging reactive oxygen/nitrogen and disrupting the Ca<sup>2+</sup>-ROS amplification loop. Importantly, SAA stabilized in the LDH matrix undergoes spatiotemporally controlled release relying on the acidic pH of the post-ischemic environment, and targeted, precise administration reprograms microglia to an M2 phenotype, helping to restore brain homeostasis.
Results & conclusions: In a mouse model of transient ischemia, S-E@LDH reduces neuronal damage, neuroinflammation and cerebral edema, improving motor function. This multi-targeted nanosheet offers spatiotemporally controlled therapy for IS, addressing its complex pathogenesis.
Abstract © the authors / Journal of Controlled Release (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.jconrel.2026.114737 · PubMed 41724243.
Why it matters for pharma & biotech
- Relevant to Pharmacology & Drug Discovery teams tracking Journal of Controlled Release for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Journal of Controlled Release study find?
This multi-targeted nanosheet offers spatiotemporally controlled therapy for IS, addressing its complex pathogenesis.
What type of study is this?
It is a preclinical (animal / model) study, published in Journal of Controlled Release in 2026. In the acute phase, cellular damage is reduced by effectively chelating Ca<sup>2+</sup>, scavenging reactive oxygen/nitrogen and disrupting the Ca<sup>2+</sup>-ROS amplification loop.
Where can I read the original paper?
The original is at the publisher via DOI 10.1016/j.jconrel.2026.114737. PubMed ID: 41724243. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/multiaspect-layered-double-hydroxide-nanohybrid-counteracts-pathophysiol-114737/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides